26 Apr GENESIS Biomed and FI Group create GENESIS Tech Transfer Boost, a new investment vehicle that will invest in early stage projects from healthcare research
This post is also available in: ES (Spanish)
The vehicle, of initial size of €1m, will invest tickets between 25-100k per project.
GENESIS Biomed will be the managing entity of the vehicle.
The consultancy firms GENESIS Biomed and FI Group, leaders in biomedical strategic consultancy and in advising on the financing of R&D&I and the management of calls for public grants and funding, respectively, have created GENESIS Tech Transfer Boost, a new investment vehicle initially endowed with €1M that will invest in early stage projects in the field of health research.
In the words of Josep Lluís Falcó, CEO of GENESIS Biomed, “with the creation of this new vehicle we intend to invest in very early projects, even in the pre-constitutive phase, which will be spinoffs in the near future, and which are now when they most need an economic contribution in order to generate value and be attractive in the future for large investors in the sector“.
GENESIS Tech Transfer Boost will invest tickets from 25k to 100k per project, in exchange for equity in the companies already created, or in exchange for an equity commitment in the projects that will become spin-offs at a later stage. This funding will be aimed at generating maximum value in the projects invested, from the generation of key proofs of concept to patent protection of the results, including the preparation of the business plan and the application for regional, national, and international public funding. The investment focus will be very cross-cutting, including pharma, Medtech, diagnostics and digital health projects.
The vehicle has been created thanks to the synergy between the consulting firms GENESIS Biomed and FI Group, which have been collaborating for several years with several common success stories, such as the companies Corify Care, CreatSens, Cornea Project, Oxolife, Telara Pharma, Aortyx, Mowoot, ADmit Therapeutics, Endolipid Therapeutics, AptaTargets and Anais Medical, among others. In the words of Iván Ruiz, CEO of FI Group, “With this agreement we enable access to the most professional and extensive public-private financing of projects in a sector that is crucial for the future of our economy, health research, where after what happened with COVID, it is even more important”.
The company Crowd4Ventures, led by Agustí Soler, has also participated in the constitution of the vehicle. He points out that “The entry into this investment vehicle allows us to actively participate in very early stages of biotech companies, a stage that was not covered by existing funds and therefore represents an opportunity to fill this gap and helps to consolidate technology transfer in our country“.
This new vehicle will base its scouting on all projects coming from the main Health Research Institutes in Spain, as well as from the nodes of the ITEMAS network.
This investment model has already been previously validated by the vehicle that the consulting firm GENESIS Biomed created in 2017, called GENESIS Ventures, which has invested in 14 biomedical projects. Of these 14 projects, the exit scenario has already taken place in one, while 6 others have already closed successive investment rounds with different investors, and 5 others are in the process of investment rounds. The valuation of the GENESIS Ventures portfolio has reached a multiplier of x3.5 in 4 years.
Founded in 2017, GENESIS Biomed is a company specialising in the genesis of biotech companies that develop innovative solutions to improve people’s health and quality of life. Headquartered in Barcelona and with offices in Madrid, GENESIS Biomed is a reference player at national level and with a clear international vocation that has a team of 14 highly qualified, specialised, and experienced professionals. The company, which is firmly committed to entrepreneurship and business development in the biomedical sector, is a leading consultancy firm in the sector in Spain for researchers, research centres and investors who want to develop spin-offs and start-ups.
For more information about Genesis Biomed, please contact:
email@example.com / +34 93 403 58 53
International consulting firm with more than 20 years of experience and 38 offices around the world. The Group is made up of more than 1400 professionals, 80% of whom are graduates and doctors in different areas of knowledge. With a 100% client focus, they work to become a strategic partner in the management of R&D&I financing, from the gestation of the project idea to its commercialisation.
Investment club established in 2021 with the aim of democratising professional investment in specialised funds.